Carrie Carbone
Family · Winter Haven, FLNPI 1659746139
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 595 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 11.7% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 595 payments — averaging $17.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Bayer$903
- Amgen$776
- Dexcom, Inc.$758
- Novo Nordisk$639
- Merck$629
- plus $6K from 33 others
What the payments were for
- Food & beverage$10,406100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 70 | $1,215 |
| Bayer | 64 | $903 |
| Amgen | 57 | $776 |
| Dexcom, Inc. | 44 | $758 |
| Novo Nordisk | 42 | $639 |
| Merck | 36 | $629 |
| AbbVie | 29 | $578 |
| Pfizer | 32 | $577 |
| Boehringer Ingelheim | 23 | $479 |
| Novartis | 19 | $362 |
| Daiichi Sankyo Inc. | 20 | $354 |
| Lilly USA, LLC | 17 | $335 |
| Exact Sciences | 13 | $330 |
| E.r. Squibb & Sons, L.L.C. | 17 | $298 |
| Astellas Pharma US Inc | 11 | $274 |
| Johnson & Johnson | 14 | $258 |
| Esperion Therapeutics, Inc. | 15 | $256 |
| Abbott | 10 | $221 |
| Amarin Pharma, Inc. | 11 | $201 |
| GSK | 11 | $194 |
| Sumitomo Pharma America, Inc. | 6 | $104 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $80 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $79 |
| Sanofi-aventis U.S. LLC | 4 | $66 |
| Cequr Corporation | 1 | $53 |
| Lifescan, Inc. | 2 | $49 |
| Boston Scientific | 2 | $46 |
| Averitas Pharma Inc. | 2 | $45 |
| Paratek Pharmaceuticals, Inc. | 2 | $42 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Medtronic | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Inogen, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
How this compares
$10,420 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 46 | $76,665 |
| EliquisApixaban | 45 | $49,643 |
| MounjaroTirzepatide | 36 | $41,116 |
| JardianceEmpagliflozin | 26 | $36,306 |
| FarxigaDapagliflozin Propanediol | 25 | $23,294 |
| EntrestoSacubitril/Valsartan | 13 | $17,764 |
| Repatha SureclickEvolocumab | 19 | $13,401 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 38 | $1,809 |
| Atorvastatin Calcium | 219 | $1,475 |
| Gabapentin | 70 | $1,107 |
| Rosuvastatin Calcium | 118 | $1,082 |
| Levothyroxine Sodium | 102 | $1,033 |
| Potassium Citrate ErPotassium Citrate | 14 | $902 |
| Losartan Potassium | 85 | $808 |
| Pravastatin Sodium | 36 | $686 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $639 | $76,66546 claims |
| PfizerEliquis | $577 | $49,64345 claims |
| Lilly USA, LLCMounjaro | $335 | $41,11636 claims |
| Boehringer IngelheimJardiance | $479 | $36,30626 claims |
| AstraZenecaFarxiga | $1,215 | $23,29425 claims |
| NovartisEntresto | $362 | $17,76413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Winter Haven
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
- Ronda CrewsJax Bch$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.